The Quantellect read.As of Nov 19, 2026, 5 active firms cover Kazia Therapeutics Ltd ADR: 5 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $18.00 to $40.00 (about 2.2x), a sign of real disagreement on valuation. The average target of $28.80 sits 425% above the current $5.49. The rating mix has stayed broadly stable, with Buy-side ratings easing from 6 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.00 next quarter toward $-0.01 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 active firms
Buy
Strong Buy00%
Buy5100%
Neutral00%
Sell00%
Strong Sell00%
Based on 5 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$28.80
+424.6% upside
Average target across 5 active firms as of Nov 19, 2026 vs $5.49 current
Highest Target$40.00
Average Target$28.80
Lowest Target$18.00
Detailed analyst forecasts for KZIA
Showing 1–4 of 4 named analysts shown · 5 active firms in the rating projection
As of Nov 19, 2026, 5 of 5 active firms rate KZIA a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
KZIA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.00
Range $-0.00 – $-0.00 · 1 analysts
Next period, 1 analysts expect Kazia Therapeutics Ltd ADR to earn $-0.00 a share (range $-0.00 – $-0.00), versus — a year earlier. Full-year consensus is $-0.01, growing to $-0.01 the year after.
REVENUE · NEXT QUARTER
—
Range — – — · 1 analysts
Revenue is expected to reach — (range — – —). Full-year consensus is $809.3K, rising to $445.7K next year.
Top analysts covering Kazia Therapeutics Ltd ADR
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on KZIA.
#1
Sean Lee
HC Wainwright & Co. · Rank #344
Buy
$18.00+227.9% to target
Overall win rate
40%
+ Follow
#2
John Newman
Canaccord Genuity · Rank #538
Buy
$29.00+428.2% to target
Overall win rate
31%
+ Follow
#3
Jason McCarthy
Maxim Group · Rank #567
Buy
$15.00+173.2% to target
Overall win rate
30%
+ Follow
#4
NR
Naz Rahman
Maxim Group · Rank #578
Buy
$30.00+446.4% to target
Overall win rate
27%
+ Follow
#5
KY
Kambiz Yazdi
BTIG
Buy
$40.00+628.6% to target
Coverage
—
+ Follow
KZIA stock forecast FAQ
What is KZIA's average 12-month price target?+
The 5 active firms with a live target average $28.80 for Kazia Therapeutics Ltd ADR over the next 12 months, ranging from a $40.00 high to a $18.00 low, as of Nov 19, 2026.
Is KZIA stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 5 active firms as of Nov 19, 2026, 5 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for KZIA?+
The Street-high target is $40.00 (BTIG), and the Street-low is $18.00 (HC Wainwright & Co.). The average of all 5 active-firm targets is $28.80.
How many active Wall Street firms cover KZIA?+
5 active firms have a recognized rating on Kazia Therapeutics Ltd ADR as of Nov 19, 2026, and 5 active firms carry a live 12-month price target.
Who is the most accurate analyst covering KZIA?+
Among analysts who currently cover KZIA, Sean Lee of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #344). Their current call is Buy with a $18.00 target.
What is Kazia Therapeutics Ltd ADR's projected EPS for next quarter?+
The consensus estimate is $-0.00 per share (range $-0.00 – $-0.00) across 1 analysts. Full-year EPS is projected at $-0.01, rising to $-0.01 the following year.
How much revenue is Kazia Therapeutics Ltd ADR expected to report next quarter?+
Consensus revenue is — (range — – —). Full-year revenue is projected at $809.3K, growing to $445.7K next year.
Have analysts been upgrading or downgrading KZIA lately?+
As of Nov 19, 2026, 5 of 5 active firms rate KZIA a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their KZIA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.